Jun. 11, 2019News & Opinions
North America should continue to lead global pharmaceutical sales up to 2022, with $635 billion in revenue expected that year, drugmaker AstraZeneca said in a recently published outlook on the industry.
May. 08, 2019News & Opinions
Anglo-Swedish drugmaker AstraZeneca is to collaborate with French biotech Transgene, part of Institut Mérieux, to discover and develop immunotherapies for treating cancers and infectious diseases.
Apr. 03, 2019News & Opinions
In a move to accelerate the development of its oncology franchise, AstraZeneca has agreed a $6.9 billion deal with Japanese pharma major Daiichi Sankyo to share rights to a new breast cancer drug called DS-8201.
Dec. 14, 2018News & Opinions
US biopharma AVEO Oncology is collaborating with Anglo-Swedish drug major AstraZeneca on a combined treatment for liver cancer.
Nov. 14, 2018News & Opinions
Anglo-Swedish drugmaker AstraZeneca has sold US right for its Synagis infant respiratory drug to Swedish Orphan Biovitrum (Sobi) for an upfront sum of $1.5 billion. The payment consists of $1 billion in cash and $500 million in Sobi ...
Nov. 09, 2018News & Opinions
AstraZeneca, the British-Swedish pharma major, is selling rights outside the US for the respiratory drugs Alvesco, Omnaris, and Zetonna. Buyer is Zug, Switzerland-based Covis Pharma, which acquired the US ...
Nov. 08, 2018News & Opinions
AstraZeneca is selling certain rights to Nexium and Vimovo to German drugmaker Grünenthal, having decided the drugs falls outside its main therapy areas of oncology, cardiovascular, renal & metabolism and respiratory.
Jul. 31, 2018News & Opinions
Anglo-Swedish drugmaker AstraZeneca has agreed to sell commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Germany’s Cheplapharm ...
Mar. 05, 2018News & Opinions
MedImmune, the biologics R&D arm of Anglo-Swedish drugmaker AstraZeneca, is spinning out six molecules from its early-stage inflammation and autoimmunity programs into new independent biotech, Viela Bio.
Mar. 01, 2018News & Opinions
The US Food and Drug Administration (FDA) has approved AstraZeneca and MedImmune’s immunotherapy Imfinzi (durvalumab) to treat patients with a certain form of lung cancer.
The latest information directly via newsletter.